--12-31false0001865782Q20001865782btsg:HarvestGroveLTCLLCMember2023-12-310001865782btsg:TangibleEquityUnitsMember2024-01-012024-06-3000018657822023-06-300001865782us-gaap:CommonStockMemberus-gaap:IPOMember2024-01-310001865782btsg:MonitoringAgreementMemberbtsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001865782btsg:MedicareDMember2023-04-012023-06-3000018657822024-01-242024-01-240001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2024-04-012024-06-300001865782btsg:IndefiniteLivedLicensesMember2024-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001865782btsg:RevolvingCreditLoansPayableToLendersAtSofrPlusApplicableMarginMember2024-06-300001865782us-gaap:LicensingAgreementsMember2024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2024-04-012024-06-300001865782btsg:MedicareBMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberbtsg:MedicaidMember2023-01-012023-06-300001865782btsg:HarvestGroveLTCLLCMember2024-01-012024-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-04-012024-06-300001865782us-gaap:ServiceMember2023-01-012023-06-300001865782us-gaap:NoncontrollingInterestMember2023-12-310001865782btsg:NotesPayableAndOtherMember2024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2024-04-012024-06-300001865782btsg:KkrCapitalMarketsLlcMember2024-01-012024-03-310001865782btsg:PharmacySolutionsMemberbtsg:CommercialInsuranceMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782srt:MinimumMemberus-gaap:TradeNamesMember2024-06-300001865782us-gaap:ProductMember2023-04-012023-06-3000018657822024-01-012024-01-310001865782btsg:PrivateAndOtherMember2024-04-012024-06-300001865782btsg:MedicareDMember2024-01-012024-06-300001865782us-gaap:CommonStockMember2023-12-310001865782us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMember2023-04-012023-06-300001865782us-gaap:RetainedEarningsMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2023-01-012023-06-300001865782btsg:SwinglineBaseRatePayableToLendersAtAbrPlusApplicableMarginMember2023-12-310001865782us-gaap:RetainedEarningsMember2024-04-012024-06-300001865782btsg:FirstLienCreditAgreementMember2024-02-212024-02-210001865782btsg:PharmacySolutionsMemberbtsg:CommercialInsuranceMember2024-01-012024-06-300001865782us-gaap:ServiceMember2024-01-012024-06-300001865782btsg:AccruedLiabilitiesCurrentMember2023-12-310001865782btsg:ProviderServicesMember2023-01-012023-06-300001865782us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:IncomeApproachValuationTechniqueMemberbtsg:ContingentConsiderationMember2023-12-310001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2023-01-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2023-01-012023-06-300001865782us-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782btsg:GreaterThanFifteenPointTwoEightMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782us-gaap:CustomerRelationshipsMember2023-12-310001865782btsg:PharmacySolutionsMember2024-01-012024-06-300001865782btsg:KkrCapitalMarketsLlcMember2024-04-012024-06-300001865782us-gaap:ProductMember2023-01-012023-06-300001865782us-gaap:RevolvingCreditFacilityMemberbtsg:SwinglineLoansMember2024-01-012024-06-300001865782btsg:ProviderServicesMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareCMember2023-04-012023-06-300001865782btsg:AmortizingNotesMember2024-06-300001865782btsg:PharmacySolutionsMemberbtsg:PrivateAndOtherMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicaidMember2024-01-012024-06-300001865782us-gaap:RetainedEarningsMember2023-01-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2023-01-012023-06-300001865782us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001865782us-gaap:RetainedEarningsMember2023-03-310001865782srt:MaximumMemberus-gaap:CustomerRelationshipsMember2024-06-300001865782btsg:LcFacilityMember2023-12-310001865782btsg:GatewayPediatricTherapyLlcMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicaidMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareBMember2023-04-012023-06-300001865782btsg:FirstLienIncrementalTermLoanTrancheB4PayableToLendersAtSofrPlusApplicableMarginMember2024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2024-04-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberbtsg:PrivateAndOtherMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMember2024-04-012024-06-300001865782btsg:SeniorAmortizingNoteMember2024-01-012024-01-310001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareBMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicaidMember2024-04-012024-06-300001865782us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001865782btsg:TangibleEquityUnitsMember2024-04-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberbtsg:PrivateAndOtherMember2023-04-012023-06-300001865782btsg:TangibleEquityUnitsMember2024-06-300001865782btsg:LcFacilityMember2024-01-012024-06-300001865782us-gaap:CommonStockMember2024-01-012024-06-300001865782btsg:CreditAgricoleCorporateAndInvestmentBankMember2024-06-300001865782btsg:ProviderServicesMemberbtsg:CommercialInsuranceMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2023-01-012023-06-300001865782btsg:CovenantsNotToCompleteMembersrt:MinimumMember2024-06-300001865782btsg:CommercialInsuranceMember2024-01-012024-06-300001865782us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001865782srt:MinimumMemberbtsg:EqualToOrLessThanFifteenPointTwoEightButGreaterThanOrEqualToThirteenPointZeroZeroMember2024-06-300001865782us-gaap:ProductMember2024-04-012024-06-300001865782srt:MaximumMember2024-06-300001865782btsg:ProviderServicesMember2024-06-300001865782btsg:MedicareDMember2024-04-012024-06-300001865782us-gaap:OtherIntangibleAssetsMember2023-12-310001865782us-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:PrivateAndOtherMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMember2023-12-310001865782us-gaap:FairValueMeasurementsRecurringMemberus-gaap:IncomeApproachValuationTechniqueMember2023-12-310001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2023-04-012023-06-300001865782us-gaap:TradeNamesMember2024-06-300001865782btsg:CommercialInsuranceMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2023-01-012023-06-300001865782btsg:CommercialInsuranceMember2023-01-012023-06-300001865782btsg:DoctorPayorNetworkMembersrt:MinimumMember2024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareCMember2024-01-012024-06-300001865782btsg:SecondLienCreditAgreementMember2024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareAMember2024-04-012024-06-300001865782us-gaap:FairValueMeasurementsRecurringMemberus-gaap:IncomeApproachValuationTechniqueMember2024-06-300001865782btsg:MedicareAMember2023-04-012023-06-300001865782btsg:OtherMember2024-01-012024-06-300001865782us-gaap:LicensingAgreementsMember2023-12-310001865782btsg:RevolvingCreditLoansPayableToLendersAtSofrPlusApplicableMarginMember2023-12-310001865782btsg:TrancheB4TermLoanMemberbtsg:FirstLienCreditAgreementMember2024-02-210001865782us-gaap:RevolvingCreditFacilityMemberbtsg:AlternateBaseRateMemberbtsg:SwinglineLoansMember2024-02-212024-02-210001865782btsg:LongTermLiabilitiesCurrentMember2024-06-300001865782btsg:LessThanThirteenPointZeroZeroMembersrt:MaximumMember2024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareBMember2023-01-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareBMember2024-04-012024-06-300001865782us-gaap:CommonStockMember2024-01-012024-01-310001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100018657822023-01-012023-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-03-310001865782btsg:HarvestGroveLTCLLCMember2024-06-300001865782btsg:FirstLienCreditAgreementMember2019-03-052019-03-050001865782btsg:MedicareCMember2024-04-012024-06-300001865782us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001865782btsg:ProviderServicesMemberbtsg:MedicareBMember2023-04-012023-06-300001865782btsg:CreditAgricoleCorporateAndInvestmentBankMember2024-01-012024-06-300001865782btsg:SHCMedicalPartnersLLCMember2024-06-300001865782btsg:TrancheB1TermLoanMemberbtsg:FirstLienCreditAgreementMember2019-03-050001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-12-310001865782btsg:PharmacySolutionsMemberbtsg:MedicareDMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberbtsg:CommercialInsuranceMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782btsg:MorganStanleyMember2024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareAMember2023-01-012023-06-300001865782btsg:TwentyTwentyFourEquityIncentivePlanMember2024-01-012024-06-300001865782us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001865782us-gaap:RetainedEarningsMember2023-12-310001865782btsg:ProviderServicesMemberbtsg:MedicareAMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2024-01-012024-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-03-3100018657822024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareDMember2024-04-012024-06-300001865782btsg:GatewayPediatricTherapyLlcMember2023-12-310001865782us-gaap:CommonStockMember2023-03-310001865782us-gaap:NoncompeteAgreementsMemberbtsg:TwoThousandTwentyFourAcquisitionsMember2024-01-012024-06-300001865782btsg:MedicareCMember2023-01-012023-06-300001865782us-gaap:MarketApproachValuationTechniqueMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001865782btsg:PharmacySolutionsMemberbtsg:PrivateAndOtherMember2023-01-012023-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-12-310001865782us-gaap:LetterOfCreditMember2024-06-300001865782us-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareBMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareCMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberbtsg:PrivateAndOtherMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareAMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareBMember2024-04-012024-06-300001865782btsg:SeniorAmortizingNoteMember2024-05-010001865782btsg:MonitoringAgreementMemberbtsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMember2024-01-012024-01-310001865782btsg:PharmacySolutionsMemberbtsg:MedicareBMember2023-01-012023-06-300001865782btsg:FirstLienPayableToLendersAtSofrPlusApplicableMarginMember2023-12-310001865782btsg:GatewayPediatricTherapyLlcMemberus-gaap:AccountsPayableMember2024-06-300001865782us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2023-04-012023-06-300001865782btsg:TwentyTwentyFourEquityIncentivePlanMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782us-gaap:NoncontrollingInterestMember2024-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001865782btsg:EqualToOrLessThanFifteenPointTwoEightButGreaterThanOrEqualToThirteenPointZeroZeroMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareBMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2024-04-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782srt:MinimumMemberus-gaap:LicensingAgreementsMember2024-06-300001865782us-gaap:CommonStockMemberus-gaap:IPOMember2024-01-012024-01-310001865782us-gaap:ServiceMember2023-04-012023-06-300001865782btsg:GatewayPediatricTherapyLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-06-300001865782btsg:ProviderServicesMember2023-12-310001865782btsg:PharmacySolutionsMemberbtsg:MedicareDMember2023-04-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicaidMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782btsg:MedicareCMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2023-04-012023-06-300001865782btsg:SHCMedicalPartnersLLCMember2023-12-310001865782btsg:TangibleEquityUnitsMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782us-gaap:CommonStockMember2023-06-300001865782btsg:PharmacySolutionsMember2023-01-012023-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-012023-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareBMember2024-04-012024-06-300001865782us-gaap:RetainedEarningsMember2024-03-310001865782btsg:TwoThousandTwentyThreeAcquisitionMemberus-gaap:TradeNamesMember2024-01-012024-06-300001865782btsg:PrivateAndOtherMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2024-04-012024-06-300001865782srt:MinimumMember2024-06-300001865782us-gaap:RevolvingCreditFacilityMemberbtsg:LcSublimitMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareDMember2024-04-012024-06-300001865782btsg:CovenantsNotToCompleteMember2024-06-300001865782btsg:SecondLienPayableToLendersAtSofrPlusApplicableMarginMember2023-12-310001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-04-012023-06-300001865782us-gaap:RevolvingCreditFacilityMember2024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMember2023-01-012023-12-3100018657822024-01-310001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2024-04-012024-06-300001865782us-gaap:RevolvingCreditFacilityMember2024-02-212024-02-2100018657822022-12-310001865782us-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:CommercialInsuranceMember2023-04-012023-06-300001865782us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMember2024-02-212024-02-210001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2024-04-012024-06-3000018657822024-04-012024-06-300001865782btsg:MedicareBMember2023-04-012023-06-300001865782btsg:MedicareAMember2023-01-012023-06-300001865782btsg:ProviderServicesMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782btsg:DoctorPayorNetworkMembersrt:MaximumMember2024-06-300001865782btsg:MedicareAMember2024-01-012024-06-300001865782us-gaap:LetterOfCreditMember2023-12-310001865782us-gaap:CommonStockMember2024-03-310001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2023-04-012023-06-300001865782btsg:DoctorPayorNetworkMember2024-06-300001865782btsg:FirstLienCreditAgreementMember2024-02-210001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareAMember2023-01-012023-06-300001865782us-gaap:LicensingAgreementsMembersrt:MaximumMember2024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2023-01-012023-06-300001865782btsg:TwoThousandTwentyFourAcquisitionsMember2024-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMemberus-gaap:CustomerRelationshipsMember2024-01-012024-06-300001865782us-gaap:RetainedEarningsMember2022-12-310001865782btsg:ProviderServicesMemberbtsg:MedicareCMember2024-04-012024-06-300001865782us-gaap:RevolvingCreditFacilityMember2023-12-310001865782us-gaap:CommonStockMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareBMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2023-01-012023-06-3000018657822024-01-250001865782btsg:PharmacySolutionsMemberbtsg:MedicareDMember2023-01-012023-06-300001865782btsg:MorganStanleyMember2024-01-012024-06-300001865782btsg:MedicareBMember2024-04-012024-06-300001865782btsg:TwoThousandTwentyFourAcquisitionsMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:PrivateAndOtherMember2023-04-012023-06-300001865782btsg:CreditSuisseMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:CommercialInsuranceMember2024-04-012024-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2024-01-012024-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-06-300001865782btsg:CreditSuisseMember2024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2023-01-012023-06-300001865782us-gaap:ServiceMember2024-04-012024-06-300001865782us-gaap:NoncontrollingInterestMember2024-03-310001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001865782btsg:MedicaidMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberbtsg:PrivateAndOtherMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782btsg:HarvestGroveLTCLLCMember2023-01-012023-06-300001865782us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001865782btsg:LcFacilityMember2024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782btsg:GatewayPediatricTherapyLlcMember2024-03-012024-03-010001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2023-04-012023-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMember2023-04-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2024-04-012024-06-300001865782us-gaap:NoncontrollingInterestMember2024-01-012024-06-300001865782btsg:GreaterThanFifteenPointTwoEightMembersrt:MinimumMember2024-06-300001865782us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001865782us-gaap:CommonStockMember2024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2024-04-012024-06-300001865782us-gaap:RetainedEarningsMember2023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2024-04-012024-06-300001865782us-gaap:RetainedEarningsMember2024-06-300001865782btsg:SHCMedicalPartnersLLCMember2024-01-012024-06-300001865782btsg:TangibleEquityUnitsMember2024-01-012024-01-310001865782btsg:NotesPayableAndOtherMember2023-12-310001865782btsg:TwoThousandTwentyFourAcquisitionsMember2024-04-012024-06-300001865782btsg:MonitoringAgreementMemberbtsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001865782btsg:TangibleEquityUnitsMember2023-04-012023-06-300001865782btsg:TangibleEquityUnitsMember2024-01-012024-06-300001865782btsg:SwinglineBaseRatePayableToLendersAtAbrPlusApplicableMarginMember2024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicaidMember2023-04-012023-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2023-01-012023-06-3000018657822024-07-300001865782btsg:MedicaidMember2024-04-012024-06-3000018657822024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareCMember2024-01-012024-06-300001865782btsg:OtherMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberbtsg:MedicaidMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2024-01-012024-06-300001865782btsg:TwoThousandTwentyFourAcquisitionsMemberus-gaap:CustomerRelationshipsMember2024-01-012024-06-300001865782srt:MinimumMember2024-01-012024-06-300001865782btsg:GatewayPediatricTherapyLlcMemberus-gaap:RetainedEarningsMember2024-03-010001865782btsg:ProviderServicesMemberbtsg:PrivateAndOtherMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMember2024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2024-04-012024-06-300001865782btsg:MedicaidMember2024-01-012024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareCMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2024-01-012024-06-300001865782us-gaap:OtherIntangibleAssetsMembersrt:MaximumMember2024-06-300001865782btsg:PrivateAndOtherMember2023-04-012023-06-300001865782btsg:CommercialInsuranceMember2023-04-012023-06-300001865782btsg:KkrCapitalMarketsLlcMember2023-04-012023-06-300001865782btsg:GatewayPediatricTherapyLlcMember2024-01-012024-03-310001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2023-01-012023-06-300001865782us-gaap:OtherIntangibleAssetsMember2024-06-300001865782us-gaap:CommonStockMember2024-01-012024-06-300001865782btsg:LongTermLiabilitiesNoncurrentMember2023-12-310001865782btsg:PharmacySolutionsMemberbtsg:TwoThousandTwentyThreeAcquisitionMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareAMember2024-01-012024-06-300001865782btsg:MonitoringAgreementMemberbtsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMember2024-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberbtsg:TwoThousandTwentyThreeAcquisitionMember2024-01-012024-06-300001865782btsg:TangibleEquityUnitsMember2024-01-310001865782us-gaap:RetainedEarningsMember2024-01-012024-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMember2023-01-012023-06-300001865782btsg:MedicareDMember2023-01-012023-06-3000018657822024-03-310001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001865782btsg:ProviderServicesMemberbtsg:CommercialInsuranceMember2024-01-012024-06-300001865782btsg:IndefiniteLivedLicensesMember2023-12-310001865782us-gaap:CommonStockMember2023-01-012023-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMemberus-gaap:LicensingAgreementsMember2024-01-012024-06-300001865782us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001865782btsg:LessThanThirteenPointZeroZeroMember2024-01-012024-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMember2024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareAMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareAMember2024-04-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2023-04-012023-06-300001865782us-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782us-gaap:MarketApproachValuationTechniqueMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicaidMember2024-04-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2023-01-012023-06-300001865782btsg:PharmacySolutionsMemberbtsg:PrivateAndOtherMember2024-04-012024-06-300001865782btsg:PrivateAndOtherMember2024-01-012024-06-300001865782us-gaap:CommonStockMember2022-12-310001865782btsg:TwoThousandTwentyFourAcquisitionsMemberus-gaap:LicensingAgreementsMember2024-01-012024-06-300001865782us-gaap:TradeNamesMembersrt:MaximumMember2024-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2023-04-012023-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2023-04-012023-06-300001865782btsg:MedicaidMember2023-04-012023-06-300001865782btsg:CovenantsNotToCompleteMember2023-12-310001865782btsg:LongTermLiabilitiesNoncurrentMember2024-06-300001865782us-gaap:CustomerRelationshipsMember2024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareBMember2024-01-012024-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMember2024-01-012024-06-300001865782btsg:TwoThousandTwentyFourAcquisitionsMemberus-gaap:TradeNamesMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:CommercialInsuranceMember2023-04-012023-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMemberus-gaap:NoncompeteAgreementsMember2024-01-012024-06-300001865782btsg:OtherMember2024-04-012024-06-300001865782btsg:EqualToOrLessThanFifteenPointTwoEightButGreaterThanOrEqualToThirteenPointZeroZeroMembersrt:MaximumMember2024-06-300001865782btsg:MedicareCMember2023-04-012023-06-3000018657822023-12-310001865782btsg:SeniorAmortizingNoteMember2024-01-310001865782btsg:SecondLienCreditAgreementMember2024-01-012024-03-310001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicaidMember2023-04-012023-06-300001865782us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-01-012024-06-3000018657822023-03-310001865782btsg:PharmacySolutionsMemberbtsg:MedicareCMember2024-04-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:PrivateAndOtherMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareCMember2024-01-012024-06-300001865782btsg:FirstLienCreditAgreementMemberbtsg:TrancheB3TermLoanMember2021-12-310001865782btsg:TwentySeventeenStockPlanMember2024-06-300001865782btsg:ProviderServicesMemberbtsg:CommercialInsuranceMember2023-04-012023-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMemberbtsg:PharmacySolutionsAndProviderServicesMember2023-01-012023-12-310001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2023-04-012023-06-300001865782btsg:MedicareAMember2024-04-012024-06-300001865782btsg:TrancheB2TermLoanMemberbtsg:FirstLienCreditAgreementMember2020-12-310001865782btsg:CovenantsNotToCompleteMembersrt:MaximumMember2024-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareBMember2024-01-012024-06-300001865782btsg:OtherMember2023-01-012023-06-300001865782us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:IncomeApproachValuationTechniqueMemberbtsg:ContingentConsiderationMember2024-06-300001865782btsg:DoctorPayorNetworkMember2023-12-310001865782srt:MinimumMemberus-gaap:CustomerRelationshipsMember2024-06-300001865782btsg:PharmacySolutionsMemberbtsg:MedicareCMember2023-01-012023-06-300001865782btsg:PrivateAndOtherMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782btsg:TangibleEquityUnitsMember2023-01-012023-06-300001865782us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001865782btsg:MonitoringAgreementMemberbtsg:KohlbergKravisRobertsCoLPAndWalgreensBootsAllianceIncMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001865782btsg:FirstLienIncrementalTermLoansTranchesB2AndB3PayableToLendersAtSofrPlusApplicableMarginMember2023-12-310001865782us-gaap:TradeNamesMember2023-12-310001865782btsg:ProviderServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareAMember2024-04-012024-06-300001865782btsg:MedicareBMember2024-01-012024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001865782us-gaap:ProductMember2024-01-012024-06-300001865782us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberbtsg:MedicareDMember2024-01-012024-06-300001865782us-gaap:IPOMember2024-01-012024-06-300001865782btsg:GatewayPediatricTherapyLlcMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-3100018657822023-04-012023-06-300001865782us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberbtsg:FirstLienCreditAgreementMember2024-02-212024-02-210001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2023-04-012023-06-300001865782btsg:ProviderServicesMemberbtsg:MedicareDMember2024-01-012024-06-300001865782btsg:KkrCapitalMarketsLlcMember2023-01-012023-06-300001865782srt:MaximumMember2024-01-012024-06-300001865782btsg:ProviderServicesMember2024-01-012024-06-300001865782btsg:PharmacySolutionsAndProviderServicesMemberbtsg:TwoThousandTwentyFourAcquisitionsMember2024-01-012024-06-300001865782btsg:TwoThousandTwentyThreeAcquisitionMember2024-04-012024-06-300001865782us-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2024-06-300001865782btsg:PharmacySolutionsMemberus-gaap:SalesRevenueNetMemberbtsg:MedicareBMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-06-300001865782btsg:SHCMedicalPartnersLLCMember2023-01-012023-06-300001865782us-gaap:EmployeeStockOptionMember2024-01-012024-06-30xbrli:pureiso4217:USDxbrli:sharesbtsg:Acquisitionsbtsg:Unitxbrli:sharesbtsg:Customeriso4217:USDbtsg:Unitiso4217:USD

 

ROC

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-41938

 

BrightSpring Health Services, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

82-2956404

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

805 N. Whittington Parkway

Louisville, Kentucky

40222

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (502) 394-2100

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

6.75% Tangible Equity Units

 

BTSG

BTSGU

 

The Nasdaq Stock Market LLC

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of Registrant’s Common Stock outstanding as of July 30, 2024 was 171,457,499.

 

 

 


 

Table of Contents

 

 

 

Page

 

 

 

PART I.

FINANCIAL INFORMATION

2

 

 

 

Item 1.

Financial Statements (Unaudited)

2

 

Condensed Consolidated Balance Sheets

2

 

Condensed Consolidated Statements of Operations

3

 

Condensed Consolidated Statements of Comprehensive Income (Loss)

4

 

Condensed Consolidated Statements of Shareholders' Equity

5

 

Condensed Consolidated Statements of Cash Flows

7

 

Notes to Condensed Consolidated Financial Statements

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

44

Item 4.

Controls and Procedures

44

 

 

 

PART II.

OTHER INFORMATION

46

 

 

 

Item 1.

Legal Proceedings

46

Item 1A.

Risk Factors

46

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

46

Item 3.

Defaults Upon Senior Securities

46

Item 4.

Mine Safety Disclosures

46

Item 5.

Other Information

46

Item 6.

Exhibits

47

Signatures

48

 

i


 

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to “BrightSpring,” the “Company,” “we,” “us,” and “our” refer to BrightSpring Health Services, Inc. and its consolidated subsidiaries.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to, among other things, our operations, and financial performance. We have used the words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative version of these words, or similar terms and phrases to identify forward-looking statements.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. If any of these risks materialize, or if any of our assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, those set forth in Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2023 (our “Form 10-K”) filed with the U.S. Securities and Exchange Commission (the “SEC”). Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this Form 10-Q. Any forward-looking statement made by us in this Form 10-Q speaks only as of the date hereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

1


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

 

 

 

 

June 30, 2024

 

 

December 31, 2023

 

 

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

25,027

 

 

$

13,071

 

Accounts receivable, net of allowance for credit losses

 

 

984,758

 

 

 

881,627

 

Inventories

 

 

374,289

 

 

 

402,776

 

Prepaid expenses and other current assets

 

 

137,805

 

 

 

159,167

 

Total current assets

 

 

1,521,879

 

 

 

1,456,641

 

Property and equipment, net of accumulated depreciation of $406,233 and $368,089 at
    June 30, 2024 and December 31, 2023, respectively

 

 

245,569

 

 

 

245,908

 

Goodwill

 

 

2,626,353

 

 

 

2,608,412

 

Intangible assets, net of accumulated amortization

 

 

851,297

 

 

 

881,476

 

Operating lease right-of-use assets, net

 

 

258,647

 

 

 

267,446

 

Deferred income taxes, net

 

 

22,000

 

 

 

 

Other assets

 

 

79,336

 

 

 

72,838

 

Total assets

 

$

5,605,081

 

 

$

5,532,721

 

Liabilities, Redeemable Noncontrolling Interests, and Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Trade accounts payable

 

$

669,401

 

 

$

641,607

 

Accrued expenses

 

 

346,740

 

 

 

492,363

 

Current portion of obligations under operating leases

 

 

68,253

 

 

 

71,053

 

Current portion of obligations under financing leases

 

 

11,972

 

 

 

11,141

 

Current portion of long-term debt

 

 

48,670

 

 

 

32,273

 

Total current liabilities

 

 

1,145,036

 

 

 

1,248,437

 

Obligations under operating leases, net of current portion

 

 

195,507

 

 

 

201,655

 

Obligations under financing leases, net of current portion

 

 

24,160

 

 

 

22,528

 

Long-term debt, net of current portion

 

 

2,563,536

 

 

 

3,331,941

 

Deferred income taxes, net

 

 

 

 

 

23,668

 

Long-term liabilities

 

 

70,973

 

 

 

91,943

 

Total liabilities

 

 

3,999,212

 

 

 

4,920,172

 

Redeemable noncontrolling interests

 

 

5,936

 

 

 

27,139

 

Shareholders' equity:

 

 

 

 

 

 

Common stock, $0.01 par value, 1,500,000,000 and 137,398,625 shares authorized,
   
171,397,030 and 117,857,055 shares issued and outstanding at June 30, 2024 and
   December 31, 2023, respectively

 

 

1,714

 

 

 

1,179

 

Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and
   outstanding at June 30, 2024;
no shares authorized, issued or outstanding at
   December 31, 2023

 

 

 

 

 

 

Additional paid-in capital

 

 

1,804,965

 

 

 

771,336

 

Accumulated deficit

 

 

(226,150

)

 

 

(200,319

)

Accumulated other comprehensive income

 

 

19,025

 

 

 

12,544

 

Total shareholders' equity

 

 

1,599,554

 

 

 

584,740

 

Noncontrolling interest

 

 

379

 

 

 

670

 

Total equity

 

 

1,599,933

 

 

 

585,410

 

Total liabilities, redeemable noncontrolling interests, and equity

 

$

5,605,081

 

 

$

5,532,721

 

See accompanying notes to the condensed consolidated financial statements.

2


 

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

For the Three Months Ended

 

 

For the Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Products

 

$

2,114,491

 

 

$

1,596,839

 

 

$

4,091,526

 

 

$

3,063,841

 

Services

 

 

615,719

 

 

 

569,885

 

 

 

1,215,322

 

 

 

1,131,261

 

Total revenues

 

 

2,730,210

 

 

 

2,166,724

 

 

 

5,306,848

 

 

 

4,195,102

 

Cost of goods

 

 

1,931,760

 

 

 

1,409,249

 

 

 

3,738,860

 

 

 

2,716,230

 

Cost of services

 

 

409,417

 

 

 

385,405

 

 

 

809,564

 

 

 

772,089

 

Gross profit

 

 

389,033

 

 

 

372,070

 

 

 

758,424

 

 

 

706,783

 

Selling, general, and administrative expenses

 

 

326,619

 

 

 

292,454

 

 

 

687,943

 

 

 

575,612

 

Operating income

 

 

62,414

 

 

 

79,616

 

 

 

70,481

 

 

 

131,171

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

12,726

 

 

 

 

Interest expense, net

 

 

52,439

 

 

 

79,684

 

 

 

117,459

 

 

 

157,861

 

Income (loss) before income taxes

 

 

9,975

 

 

 

(68

)

 

 

(59,704

)

 

 

(26,690

)

Income tax benefit

 

 

(9,466

)

 

 

(2,834

)

 

 

(32,760

)

 

 

(7,180

)

Net income (loss)

 

 

19,441

 

 

 

2,766

 

 

 

(26,944

)

 

 

(19,510

)

Net loss attributable to noncontrolling interests

 

 

(478

)

 

 

(1,222

)

 

 

(1,113

)

 

 

(2,116

)

Net income (loss) attributable to BrightSpring Health Services,
       Inc. and subsidiaries

 

$

19,919

 

 

$

3,988

 

 

$

(25,831

)

 

$

(17,394

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per common share (Note 12):

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) per share - basic

 

$

0.10

 

 

$

0.03

 

 

$

(0.14

)

 

$

(0.15

)

Income (loss) per share - diluted

 

$

0.10

 

 

$

0.03

 

 

$

(0.14

)

 

$

(0.15

)

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

197,515

 

 

 

117,883

 

 

 

186,523

 

 

 

117,875

 

Diluted

 

 

208,987

 

 

 

126,449

 

 

 

186,523

 

 

 

117,875

 

See accompanying notes to the condensed consolidated financial statements.

3


 

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income (Loss)

(In thousands)

(Unaudited)

 

 

For the Three Months Ended

 

 

For the Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net income (loss)

 

$

19,441

 

 

$

2,766

 

 

$

(26,944

)

 

$

(19,510

)

Other comprehensive (loss) income, net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

(49

)

 

 

106

 

 

 

(195

)

 

 

109

 

Cash flow hedges:

 

 

 

 

 

 

 

 

 

 

 

 

Net change in fair value, net of tax (1)

 

 

3,145

 

 

 

26,159

 

 

 

21,104

 

 

 

19,807

 

Amounts reclassified to earnings, net of tax (2)

 

 

(7,186

)

 

 

(5,697

)

 

 

(14,428

)

 

 

(9,559

)

Total other comprehensive (loss) income, net of tax

 

 

(4,090

)

 

 

20,568

 

 

 

6,481

 

 

 

10,357

 

Total comprehensive income (loss)

 

 

15,351

 

 

 

23,334

 

 

 

(20,463

)

 

 

(9,153

)

Comprehensive loss attributable to redeemable noncontrolling
       interests

 

 

(339

)

 

 

(1,222

)

 

 

(822

)

 

 

(2,116

)

Comprehensive loss attributable to noncontrolling interest

 

 

(139

)

 

 

 

 

 

(291

)

 

 

 

Comprehensive income (loss) attributable to BrightSpring Health
       Services, Inc. and subsidiaries

 

$

15,829

 

 

$

24,556

 

 

$

(19,350

)

 

$

(7,037

)

 

(1)
The income tax effects of the net change in fair value were $(1,018) and $(6,833) for the three and six months ended June 30, 2024, respectively, and $(8,705) and $(6,591) for the three and six months ended June 30, 2023, respectively.
(2)
The income tax effects of amounts reclassified to earnings were $2,327 and $4,672 for the three and six months ended June 30, 2024, respectively, and $1,896 and $3,181 for the three and six months ended June 30, 2023, respectively.

See accompanying notes to the condensed consolidated financial statements.

4


 

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Shareholders’ Equity

(In thousands, except share data)

(Unaudited)

 

 

 

For the Three Months Ended June 30, 2024

 

 

Common Stock

 

 

Additional
Paid-In Capital

 

 

Accumulated Deficit

 

 

Accumulated Other Comprehensive Income

 

 

Noncontrolling
Interest

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at March 31, 2024

 

 

171,190,389

 

 

$

1,712

 

 

$

1,788,728

 

 

$

(246,069

)

 

$

23,115

 

 

$

518

 

 

$

1,568,004

 

Net income (loss) (1)

 

 

 

 

 

 

 

 

 

 

 

19,919

 

 

 

 

 

 

(139

)

 

 

19,780

 

Other comprehensive loss, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,090

)

 

 

 

 

 

(4,090

)

Share-based compensation

 

 

 

 

 

 

 

 

15,136

 

 

 

 

 

 

 

 

 

 

 

 

15,136

 

Shares issued under share-based compensation
     plan, including tax effects

 

 

107,389

 

 

 

1

 

 

 

21

 

 

 

 

 

 

 

 

 

 

 

 

22

 

Shares issued for payment of acquisition

 

 

99,252

 

 

 

1

 

 

 

1,080

 

 

 

 

 

 

 

 

 

 

 

 

1,081

 

Balances at June 30, 2024

 

 

171,397,030

 

 

$

1,714

 

 

$

1,804,965

 

 

$

(226,150

)

 

$

19,025

 

 

$

379

 

 

$

1,599,933

 

 

 

 

For the Three Months Ended June 30, 2023

 

 

Common Stock

 

 

Additional
Paid-In Capital

 

 

Accumulated Deficit

 

 

Accumulated Other Comprehensive Income

 

 

Noncontrolling
Interest

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at March 31, 2023

 

 

117,883,231

 

 

$

1,179

 

 

$

778,716

 

 

$

(67,098

)

 

$

10,981

 

 

$

 

 

$

723,778

 

Net income (1)

 

 

 

 

 

 

 

 

 

 

 

3,988

 

 

 

 

 

 

 

 

 

3,988

 

Other comprehensive income, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20,568

 

 

 

 

 

 

20,568

 

Share-based compensation

 

 

 

 

 

 

 

 

825

 

 

 

 

 

 

 

 

 

 

 

 

825

 

Balances at June 30, 2023

 

 

117,883,231

 

 

$

1,179

 

 

$

779,541

 

 

$

(63,110

)

 

$

31,549

 

 

$

 

 

$

749,159

 

(1) Net income (loss) to the Company for the three months ended June 30, 2024 and 2023 excludes $(339) and $(1,222), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.

 

5


 

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Shareholders’ Equity (continued)

(In thousands, except share data or otherwise indicated)

(Unaudited)

 

 

 

For the Six Months Ended June 30, 2024

 

 

Common Stock

 

 

Additional
Paid-In Capital

 

 

Accumulated Deficit

 

 

Accumulated Other Comprehensive Income

 

 

Noncontrolling
Interest

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2023

 

 

117,857,055

 

 

$

1,179

 

 

$

771,336

 

 

$

(200,319

)

 

$

12,544

 

 

$

670

 

 

$

585,410

 

Net loss (1)

 

 

 

 

 

 

 

 

 

 

 

(25,831

)

 

 

 

 

 

(291

)

 

 

(26,122

)

Other comprehensive income, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,481

 

 

 

 

 

 

6,481

 

Share-based compensation

 

 

 

 

 

 

 

 

39,984

 

 

 

 

 

 

 

 

 

 

 

 

39,984

 

Shares issued under share-based compensation
     plan, including tax effects

 

 

107,389

 

 

 

1

 

 

 

21

 

 

 

 

 

 

 

 

 

 

 

 

22

 

Shares issued for payment of acquisition

 

 

99,252

 

 

 

1

 

 

 

1,080

 

 

 

 

 

 

 

 

 

 

 

 

1,081

 

Extinguishment of redeemable noncontrolling
     interest

 

 

 

 

 

 

 

 

14,981

 

 

 

 

 

 

 

 

 

 

 

 

14,981

 

Issuance of common stock on initial public
     offering, net of underwriting discounts and
     commissions, and offering-related expenses
     of $
36.8 million

 

 

53,333,334

 

 

 

533

 

 

 

655,952

 

 

 

 

 

 

 

 

 

 

 

 

656,485

 

Proceeds from stock purchase contract issued
     under tangible equity units, net of
     underwriting discounts and commissions
     of $
9.1 million

 

 

 

 

 

 

 

 

321,611

 

 

 

 

 

 

 

 

 

 

 

 

321,611

 

Balances at June 30, 2024

 

 

171,397,030

 

 

$

1,714

 

 

$

1,804,965

 

 

$

(226,150

)

 

$

19,025

 

 

$

379

 

 

$

1,599,933

 

 

 

 

For the Six Months Ended June 30, 2023

 

 

Common Stock

 

 

Additional
Paid-In Capital

 

 

Accumulated Deficit

 

 

Accumulated Other Comprehensive Income

 

 

Noncontrolling
Interest

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2022

 

 

117,860,839

 

 

$

1,179

 

 

$

778,121

 

 

$

(45,716

)

 

$

21,192

 

 

$

 

 

$

754,776

 

Net loss (1)

 

 

 

 

 

 

 

 

 

 

 

(17,394

)

 

 

 

 

 

 

 

 

(17,394

)

Other comprehensive income, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,357

 

 

 

 

 

 

10,357

 

Share-based compensation

 

 

 

 

 

 

 

 

1,275

 

 

 

 

 

 

 

 

 

 

 

 

1,275

 

Shares issued under share-based compensation
     plan, including tax effects

 

 

22,392

 

 

 

 

 

 

145

 

 

 

 

 

 

 

 

 

 

 

 

145

 

Balances at June 30, 2023

 

 

117,883,231

 

 

$

1,179

 

 

$

779,541

 

 

$

(63,110

)

 

$

31,549

 

 

$

 

 

$

749,159

 

(1) Net loss to the Company for the six months ended June 30, 2024 and 2023 excludes $(822) and $(2,116), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.

See accompanying notes to the condensed consolidated financial statements.

6


 

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

For the Six Months Ended

 

 

 

June 30,

 

 

2024

 

 

2023

 

Operating activities:

 

 

 

 

 

 

Net loss

 

$

(26,944

)

 

$

(19,510

)

Adjustments to reconcile net loss to cash (used in) provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

98,993

 

 

 

100,550

 

Impairment of long-lived assets

 

 

1,980

 

 

 

6,114

 

Provision for credit losses

 

 

13,118

 

 

 

12,174

 

Amortization of deferred debt issuance costs

 

 

6,937

 

 

 

10,509

 

Share-based compensation

 

 

39,984

 

 

 

1,275

 

Deferred income taxes, net

 

 

(49,260

)

 

 

(25,755

)

Loss on extinguishment of debt

 

 

12,726

 

 

 

 

Loss on disposition of fixed assets

 

 

24

 

 

 

519

 

Other

 

 

(1,438

)

 

 

372

 

Change in operating assets and liabilities, net of acquisitions and dispositions:

 

 

 

 

 

 

Accounts receivable

 

 

(112,522

)

 

 

(105,402

)

Prepaid expenses and other current assets

 

 

21,737

 

 

 

22,110

 

Inventories

 

 

29,720

 

 

 

36,708

 

Trade accounts payable

 

 

41,329

 

 

 

(89,666

)

Accrued expenses

 

 

(153,892

)

 

 

69,682

 

Other assets and liabilities

 

 

(16,576

)

 

 

(4,988

)

Net cash (used in) provided by operating activities

 

$

(94,084

)

 

$

14,692

 

Investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

$

(45,559

)

 

$

(38,794

)

Acquisitions of businesses, net of cash acquired

 

 

(43,611

)

 

 

(25,464

)

Other

 

 

540

 

 

 

1,494

 

Net cash used in investing activities

 

$

(88,630

)

 

$

(62,764

)

Financing activities:

 

 

 

 

 

 

Long-term debt borrowings

 

$

2,566,000

 

 

$

 

Long-term debt repayments

 

 

(3,370,970

)

 

 

(15,321

)

Proceeds from issuance of common stock on initial public offering, net

 

 

656,485

 

 

 

 

Proceeds from issuance of tangible equity units, net

 

 

389,000

 

 

 

 

Borrowings of the Revolving Credit Facility, net

 

 

5,100

 

 

 

66,600

 

Payment of debt issuance costs

 

 

(43,188

)

 

 

 

Repurchase of shares of common stock

 

 

(650

)

 

 

 

Shares issued under share-based compensation plan, including tax effects

 

 

404

 

 

 

145

 

Shares issued for payment of acquisition

 

 

1,081

 

 

 

 

Payment of acquisition earn-outs

 

 

(2,656

)

 

 

 

Purchase of redeemable noncontrolling interest

 

 

(300

)

 

 

 

Payment of financing lease obligations

 

 

(5,636

)

 

 

(5,724

)

Net cash provided by financing activities

 

$

194,670

 

 

$

45,700

 

Net increase (decrease) in cash and cash equivalents

 

 

11,956

 

 

 

(2,372

)

Cash and cash equivalents at beginning of year

 

 

13,071

 

 

 

13,628

 

Cash and cash equivalents at end of year

 

$

25,027